Growth differentiation factor 15 in different stages of heart failure: Potential screening implications

Biomarkers

Volumn 15, Issue 8, 2010, Pages 671-676

  Wang, Fangfang ^a   Guo, Yanhong ^a   Yu, Haiyi ^a   Zheng, Lingbing ^a   Mi, Lin ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Biomarkers; Growth differentiation factor 15; Heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCREENING;

AGED; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE;

EID: 78649349410     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.510580     Document Type: Article

References (22)

1. Baggish AL, van Kimmenade RR, Pinto Y, Richards AM, Lainchbury J, Bayes-Genis A, Santaló M, Ordonez-Llanos J, Januzzi JL. (2010). New York Heart Association class versus amino-terminal pro-B type natriuretic peptide or acute heart failure prognosis. Biomarkers 15:307-14.
2. Bootcov MR, Bauskin AR, Valenzuela SM, et al. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94:11514-19.
3. Brown DA, Breit SN, Buring J, et al. (2002). Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 359:2159-63.
4. de Lemos JA, McGuire DK, Khera A, et al. (2009). Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 157:746-53. e2.
5. Devereux RB, Alonso DR, Lutas EM, et al. (1986). Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy fndings. Am J Cardiol 57:450-8.
6. Fox K, Garcia MA, Ardissino D, et al. (2006). Guidelines on the management of stable angina pectoris: executive summary: Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27:1341-81. (Pubitemid 43998110)
7. Hunt SA, Abraham WT, Chin MH, et al. (2005). ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-235.
8. Kempf T, Eden M, Strelau J, et al. (2006). The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351-60.
9. Kempf T, Horn-Wichmann R, Brabant G, et al. (2007a). Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53:284-91.
10. Kemp T, von HS, Peter T, et al. (2007b). Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-60.
11. Kumar S, Mohan A, Guleria R. (2006). Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11:385-405.
12. Lloyd-Jones D, Adams RJ, Brown TM, et al. (2010). Heart disease and stroke statistics-(2010) update: a report from the American Heart Association. Circulation 12: e46-e215.
13. Mancia G, De Backer G, Dominiczak A, et al. (2007). (2007) Guidelines for the management of arterial hypertension: Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462-536.
14. Matz R. (2002). Cockcroft-Gault equation and estimation of creatinine clearance. AmJ Med 112:684; author reply 684-5.
15. Pfster R, Schneider CA. (2009). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure (2008): application of natriuretic peptides. Eur Heart J 30:382-3; author reply 383.
16. Schiller NB, Shah PM, Crawford M, et al. 1989. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358-67.
17. Silver MA, Maisel A, Yancy CW, et al. (2004). BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10(5 Suppl. 3):1-30.
18. Silver MA, Pisano C. (2003). High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. Congest Heart Fail 9:127-32.
19. Tygesen K, Alpert JS, White HD. (2007). Universal definition of myocardial infarction. Eur Heart J 28:2525-38.
20. Vasan RS, Benjamin EJ, Larson MG, et al. (2002). Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288:1252-9.
21. Whitworth JA. (2003). 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-92.
22. Xu J, Kimball TR, Lorenz JN, et al. (2006). GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-50.